Drug-Free Macromolecular Therapeutics Induce Apoptosis of Patient Chronic Lymphocytic Leukemia Cells

Por Chu, Te-Wei, Kosak, Ken M., Shami, Paul J., Kopeček, Jindřich
Publicado no Drug Deliv Transl Res (2014)

Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2)-(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated...

Por Kaur, Imit, Terrazas, Moises, Kosak, Ken M, Kern, Steven E, Boucher, Kenneth M, Shami, Paul J
Publicado em 2013

EFFECT OF A PLURONIC® P123 FORMULATION ON THE NITRIC OXIDE-GENERATING DRUG JS-K

Por Kaur, Imit, Kosak, Ken M., Terrazas, Moises, Herron, James N., Kern, Steven E., Boucher, Kenneth M., Shami, Paul J.
Publicado no Pharm Res (2014)

JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C)

Por Shami, Paul J., Maciag, Anna E., Eddington, Jordan K., Udupi, Vidya, Kosak, Ken M., Saavedra, Joseph E., Keefer, Larry K.
Publicado em 2009

The Nitric Oxide Prodrug JS-K Is Effective against Non–Small-Cell Lung Cancer Cells In Vitro and In Vivo: Involvement of Reactive Oxygen Species

Por Maciag, Anna E., Chakrapani, Harinath, Saavedra, Joseph E., Morris, Nicole L., Holland, Ryan J., Kosak, Ken M., Shami, Paul J., Anderson, Lucy M., Keefer, Larry K.
Publicado em 2011